Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Feeling Safe is a new treatment programme for persecutory delusions, which promises a step change in the treatment of severe mental health problems.

Blank faced patient out walking with therapist in a street scene © Amber Anderson www.amberanderson.co.uk

The clinical trial results show that the new Feeling Safe programme is the most effective psychological treatment for persecutory delusions, with 50 percent of patients achieving recovery from their persecutory delusions.

Persecutory delusions – unfounded, strongly held beliefs that other people intend to harm us – have traditionally been regarded as a key symptom of psychiatric diagnoses such as schizophrenia. Fearing harm from those around them, patients often withdraw from ordinary life. The negative consequences of this withdrawal, for patients and family alike, can be profound.

 

 

The Feeling Safe programme was developed by researchers from the University of Oxford, who tested the treatment in a randomised controlled trial with 130 patients with persecutory delusions. The delusions had persisted despite use of standard treatments. The results are published today in the Lancet Psychiatry. Half of patients were found to achieve large benefits from the Feeling Safe programme, with a further quarter making moderate gains. The trial was funded by the National Institute for Health Research (NIHR) and the NIHR Research Professorships. It was also supported by the NIHR Oxford Health Biomedical Research Centre.

NIHR Research Professor Daniel Freeman, the developer of the Feeling Safe programme, Department of Psychiatry, University of Oxford, said:

Feeling Safe is the result of more than ten years of research and clinical practice. Its success has been built on listening carefully to patients, to really understand the causes of the problems they are facing. The trial results give us great cause for optimism in the treatment of a problem that is very common in people with psychosis, immensely distressing for patients and families, and yet often does not improve sufficiently with current treatments.

‘Over twenty sessions, the programme helps people to develop new memories of safety and addresses the factors that often maintain persecutory thoughts, such as worry, poor sleep, and low self-confidence. Feeling Safe is personalised and modular. Patients choose their preferred treatment elements and the order in which they undertake them. It’s an active therapy, based on the belief that people make gains by trying out things in everyday life. The results of the trial have been extremely pleasing. The challenge now is to reach the many thousands of people whose lives have been disrupted by severe paranoia.’

Persecutory delusions are typically treated with anti-psychotic drugs, but too many patients do not respond and side effects can be unpleasant. Four out of five patients with persecutory delusions are unemployed and spend less time in social and leisure activities and more time resting and ‘doing nothing’ compared with the general population. Life expectancy is on average 14.5 years shorter, due to largely preventable conditions such as high blood pressure, diabetes and heart disease -- illness to which inactivity is likely a major contributory factor. 

Dr Felicity Waite, clinical psychologist in the Department of Psychiatry, University of Oxford, said:

 

‘So many of the patients we visited were spending virtually all their time at home. They were acutely aware of all that they were missing out on. Our aim was to bring them back into everyday life, to help them get back to the things they like doing. The enthusiasm with which people have participated in the Feeling Safe programme, and the positive change it has brought about, has been wonderful to see.’

 A participant in the Feeling Safe trial said:

‘I was housebound. I missed out on so many things in life. I missed out on meeting my friends, family events, meals, training, sports, I was just in a very paranoid state. After a life-changing study – for me – I feel very, very safe. It worked. It really did. It helped massively. You get better sleep, feel more confident, be more active in the day. Genuinely, inside I feel very happy. It’s profoundly changed my life. I don’t have to worry any more about people potentially attacking me or thinking sometimes there’s a weapon in their pocket. That’s all floated away.’

 

To read the full paper, Comparison of a theoretically driven cognitive therapy (the Feeling Safe Programme) with befriending for the treatment of persistent persecutory delusions: a parallel, single-blind, randomised controlled trial.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

New Research Presented at the ECNP Conference - October 2021

Dr Angharad de Cates and Dr Liliana Capitão were just two of the department's researchers presenting and publishing new research at the European College of Neuropsychopharmacology (ECNP) Conference 2021, in Lisbon.

Researchers Address Mental Health Effects of the Pandemic on Young People

In a new policy briefing, a team of researchers at King’s College London and Oxford University highlight the multiple effects that the COVID-19 pandemic has had on children and young people in the UK through their education and daily life, including challenges around social isolation, academic pressures, adjusting to online learning and coping with reopening of schools.

Turing Fellowships for Over 30 Oxford Academics

Professor John Geddes, WA Handley-elect Chair of Psychiatry, is one of the thirty-three University of Oxford researchers, which have been named Turing Fellows for the 2021/22 academic year.

Simple Intervention Effectively Treats Depression During COVID 19

New research shows that even a very simple intervention, administered by non-specialists with just 15 hours of training, can effectively treat depression during COVID-19.

Over a Third of COVID-19 Patients Diagnosed with at Least One Long-COVID Symptom

A new study from the University of Oxford and the National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre (BRC) investigated long-COVID in over 270,000 people recovering from COVID-19 infection, using data from the US-based TriNetX electronic health record network.